{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Classical+Hodgkin%27s+Lymphoma&page=3", "query": { "condition": "Classical Hodgkin's Lymphoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 112, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Classical+Hodgkin%27s+Lymphoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Classical+Hodgkin%27s+Lymphoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T10:52:24.733Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00742027", "title": "Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classical Hodgkin's Lymphoma" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2008-09-16", "completion_date": "2013-08-12", "has_results": true, "last_update_posted_date": "2021-07-28", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 13, "location_summary": "Duarte, California • Atlanta, Georgia • Augusta, Georgia + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00742027" }, { "nct_id": "NCT03077828", "title": "Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphocyte-Rich Classical Hodgkin Lymphoma", "Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Recurrent Mixed Cellularity Classical Hodgkin Lymphoma", "Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma", "Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Refractory Mixed Cellularity Classical Hodgkin Lymphoma", "Refractory Nodular Sclerosis Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2017-04-21", "completion_date": "2024-12", "has_results": true, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03077828" }, { "nct_id": "NCT01712490", "title": "A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "bleomycin", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1334, "start_date": "2012-11-09", "completion_date": "2026-02-02", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712490" }, { "nct_id": "NCT06870487", "title": "A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peripheral T Cell Lymphoma", "Diffuse Large B-cell Lymphoma", "Classical Hodgkin Lymphoma", "Head and Neck Squamous Cell Carcinoma", "Melanoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "PF-08046032", "type": "DRUG" }, { "name": "Sasanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2025-05-08", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 3, "location_summary": "San Antonio, Texas • Seattle, Washington", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06870487" }, { "nct_id": "NCT00004031", "title": "SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "CHOP regimen", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "15 Years to 65 Years" }, "enrollment_count": 397, "start_date": "1997-07", "completion_date": "2013-10-31", "has_results": true, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004031" }, { "nct_id": "NCT05255601", "title": "A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Hodgkin Disease" ], "interventions": [ { "name": "Relatlimab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 5, "start_date": "2022-09-13", "completion_date": "2025-12-03", "has_results": true, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05255601" }, { "nct_id": "NCT03749018", "title": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Indolent Non-Hodgkin Lymphoma", "Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "David Bond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-01-02", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749018" }, { "nct_id": "NCT02927769", "title": "A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "brentuximab vedotin", "type": "BIOLOGICAL" }, { "name": "bendamustine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "5 Years to 30 Years" }, "enrollment_count": 72, "start_date": "2017-03-28", "completion_date": "2024-05-28", "has_results": true, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02927769" }, { "nct_id": "NCT05140382", "title": "AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Peripheral T-cell Lymphoma", "Relapsed/Refractory Classical Hodgkins Lymphoma" ], "interventions": [ { "name": "AZD4573", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 52, "start_date": "2021-12-15", "completion_date": "2024-02-16", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 6, "location_summary": "Duarte, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05140382" }, { "nct_id": "NCT02332668", "title": "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Lymphoma", "Solid Tumor", "Classical Hodgkin Lymphoma", "Microsatellite-instability-high Solid Tumor" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 370, "start_date": "2015-03-19", "completion_date": "2028-02-02", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-11T10:52:24.733Z", "location_count": 7, "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02332668" } ] }